Capmatinib for the treatment of non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• MET pathway dysregulation, including amplifications and mutations, affects 3-4% of stage IV non-squamous non-small cell lung cancer (NSCLC).
• High MET amplifications and exon 14 skipping mutations are linked to poor prognosis in NSCLC, necessitating novel therapeutic strategies.
• Capmatinib is a potent, selective small-molecule MET inhibitor demonstrating antitumor effects in NSCLC models.

Purpose of the Study:

• To review the clinical development of capmatinib for NSCLC.
• To evaluate capmatinib as monotherapy in NSCLC with MET pathway dysregulation.
• To assess capmatinib in combination with EGFR inhibitors for EGFR-mutant NSCLC with acquired resistance.

Main Methods:

• Overview of the capmatinib clinical development program in NSCLC.
• Analysis of data from the GEOMETRY Mono-1 study.
• Evaluation of capmatinib in monotherapy and combination settings.

Main Results:

• Capmatinib demonstrated high response rates in stage IV NSCLC with MET exon 14 skipping mutations, especially in the first-line setting.
• Durable responses were observed with capmatinib treatment.
• Notable responses were seen when capmatinib was combined with EGFR inhibitors in EGFR-mutant NSCLC with acquired resistance due to MET amplification.

Conclusions:

• Testing for MET exon 14 skipping mutations at diagnosis is recommended for NSCLC patients.
• Capmatinib is a promising targeted therapy for NSCLC with MET pathway alterations.
• Further results for MET-amplified NSCLC are anticipated.